Key clinical point: Real-world use of tofacitinib in U.S. rheumatoid arthritis patients was similar in safety to other biologic drugs except for a doubled rate of herpes zoster.
Major finding: After adjustment, the herpes zoster rate was 2.26-fold higher among tofacitinib recipients, compared with patients on biologic drugs.
Study details: Data from the Corrona Rheumatoid Arthritis registry, with 1,544 patients started on tofacitinib and 7,083 started on a biologic drug.
Disclosures: Dr. Kremer has been a consultant to and has received research funding from Pfizer, the company that markets tofacitinib. He has been a consultant to AbbVie, Amgen, Bristol-Myers Squibb, Genentech, and Regeneron/Sanofi, and has received research funding from AbbVie, Eli Lilly, Genentech, and Novartis. One of the coauthors on the report is a Pfizer employee.
Kremer JM et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):82-3; Abstract OP0028. doi: 10.1136/annrheumdis-2019-eular.621.